CN111733247A

CN111733247A - Application of long-chain non-coding RNA in cancer diagnosis and treatment

Info

Publication number: CN111733247A
Application number: CN202010703980.7A
Authority: CN
Inventors: 杨承刚; 孙耀兰
Original assignee: Beijing Medintell Bioinformatic Technology Co Ltd
Current assignee: Beijing Medintell Bioinformatic Technology Co Ltd
Priority date: 2020-07-21
Filing date: 2020-07-21
Publication date: 2020-10-02

Abstract

The invention discloses an application of long-chain non-coding RNA in cancer diagnosis and treatment, wherein the long-chain non-coding RNA is LOC730101, the LOC730101 is up-regulated in a laryngeal squamous cell carcinoma patient, and whether a subject suffers from laryngeal squamous cell carcinoma can be judged by detecting the expression level of LOC 730101; by down-regulating the expression of LOC730101, the proliferation and migration of cancer cells can be inhibited, thereby providing a new target for the treatment of laryngeal squamous cell carcinoma.

Description

Application of long-chain non-coding RNA in cancer diagnosis and treatment

Technical Field

The invention belongs to the field of biomedicine, and relates to application of long-chain non-coding RNA in cancer diagnosis and treatment.

Background

Laryngeal carcinoma is a common malignant tumor of the head and neck, accounts for the second place of the head and neck tumor, the incidence rate of the laryngeal carcinoma accounts for about 5 percent of the malignant tumor of the whole body, the squamous cell carcinoma accounts for about 93 to 99 percent of the total number of laryngeal carcinoma, and the laryngeal squamous cell carcinoma mostly originates from vocal cords, accounting for about 60 percent. Retrospective analysis is carried out on 306 laryngeal malignant tumors by using xanthoxinhui and the like, and the squamous cell carcinoma accounts for 99.7 percent of all malignant tumors, wherein high and medium squamous cell carcinoma is mainly used; the primary site of laryngeal carcinoma is mostly glottic, and secondly supraglottic and subglottic; smoking and drinking are closely related to the occurrence of tumors. Although the pain of patients can be relieved to different degrees by operation, radiotherapy and chemotherapy, dysfunction and local deformity are often caused after treatment, and the recurrence rate is high, thus seriously threatening the physical and psychological health of patients. The second mutation hypothesis proposed by Knudson in 1971 is a scientific prophetic for the tumorigenesis mechanism, widely accepted by researchers in tumor genetics, and has led more than 30 years of research into the molecular mechanisms of tumorigenesis. The study of different tumor related genes is the basic premise for understanding the molecular mechanism of tumorigenesis, developing gene diagnosis and gene therapy, and the cloning and localization of disease-causing genes including tumors are still an important content after the completion of human genome planning. Srinivus and the like find that the tumor can be accompanied with the change of a tumor marker at an early stage, and the detection of the content change of the tumor marker is beneficial to the early discovery of the tumor. Gene level research work will be key to the eradication of all tumors, including laryngeal cancer. Therefore, the search and cloning of the laryngeal cancer specific related gene provides a wide prospect for research on the molecular mechanism, gene diagnosis and gene therapy of laryngeal cancer.

Although the means for tumor diagnosis and treatment are changing day by day, the overall survival rate of laryngeal cancer is not improved significantly worldwide, especially for patients in advanced stages. The reason is mainly shown in three aspects: firstly, the early clinical manifestations of laryngeal cancer are various, great difficulty is brought to early diagnosis of laryngeal cancer, most patients cannot receive timely and effective treatment in early stage, and the key for improving the early diagnosis rate of laryngeal cancer is how to find the molecular marker for early diagnosis of laryngeal cancer. Secondly, the treatment of the laryngeal cancer is mainly performed by operation, radiotherapy and chemotherapy are assisted, and although the ratio of partial laryngeal resection and early glottic laryngeal cancer treatment by C02 laser is improved, the laryngeal function is completely or partially preserved, and postoperative complications are reduced, so that the quality of life of a patient is improved, the postoperative recurrence rate is still high, if a laryngeal cancer tumor promotion gene or a tumor inhibition factor can be found out, a potential drug action target point is screened out, and a foundation is laid for developing a specific vaccine or/and a new anticancer drug related to the laryngeal cancer. Thirdly, different patients have different laryngeal cancer in the aspects of pathological type, tumor differentiation degree, lesion severity degree in treatment and the like, different laryngeal cancer patients have different clinical manifestations and physical conditions, and have different sensitivities to postoperative radiotherapy and chemotherapy, and how to find a molecular marker for curative effect monitoring and prognosis judgment lays a foundation for realizing personalized treatment of laryngeal cancer.

Disclosure of Invention

The invention aims to provide a long-chain non-coding RNA marker for diagnosing laryngeal squamous cell carcinoma. The invention utilizes QPCR experiments to prove that the expression level of LOC730101 in cancer tissues of laryngeal squamous cell carcinoma patients is obviously higher than that of tissues beside cancer, so that LOC730101 can be used as a molecular marker for diagnosing laryngeal squamous cell carcinoma.

In order to test the purpose, the invention adopts the following technical scheme:

the invention provides an application of a reagent for detecting long-chain non-coding RNA expression in preparing a laryngeal squamous cell carcinoma diagnosis product. The long non-coding RNA is LOC 730101.

Further, the reagent includes a reagent used for detecting the expression level of LOC730101 by reverse transcription PCR, real-time quantitative PCR, chip detection, southern blotting, northern blotting, or in situ hybridization.

Further, the reagent comprises an amplification primer used for detecting the expression level of LOC 730101.

In a specific embodiment of the invention, the amplification primer sequences are shown as SEQ ID NO.1 and SEQ ID NO. 2.

The invention provides a product for diagnosing laryngeal squamous cell carcinoma, which diagnoses laryngeal squamous cell carcinoma by detecting the expression of the long-chain non-coding RNA in a sample.

Further, the product includes but is not limited to a chip, a kit, a strip, or a high throughput sequencing platform; the high-throughput sequencing platform is a special diagnostic tool, and with the development of high-throughput sequencing technology, the construction of an RNA expression profile of a person becomes very convenient work. By comparing the RNA expression profiles of patients with disease and normal populations, it is easy to identify which RNA abnormalities are associated with disease. Therefore, the finding that the abnormal expression of LOC730101 is related to laryngeal squamous carcinoma in high-throughput sequencing is also included in the use of LOC730101 and is also within the scope of the present invention.

The kit comprises a reagent for detecting the expression quantity of LOC730101, wherein the reagent comprises nucleic acid combined with LOC730101 or a DNA sequence thereof, and the nucleic acid comprises SYBR Green, a TaqMan probe, a molecular beacon, a double-hybridization probe or a primer and/or a probe used for detecting the expression quantity of LOC730101 by a composite probe.

The chip comprises a reagent for detecting the expression level of LOC730101, wherein the reagent comprises a nucleic acid combined with LOC730101 or a DNA sequence thereof, and the nucleic acid comprises a primer and/or a probe capable of detecting the expression level of LOC 730101.

The test paper comprises a reagent for detecting the expression quantity of LOC730101, wherein the reagent comprises a nucleic acid combined with LOC730101 or a DNA sequence thereof, and the nucleic acid comprises a primer and/or a probe capable of detecting the expression quantity of LOC 730101.

The kit may further comprise: container, instructions for use, positive control, negative control, buffer, adjuvant or solvent. For example, a solution for suspending or immobilizing cells, a detectable label or label, a solution for facilitating hybridization of nucleic acids, a solution for lysing cells, or a solution for nucleic acid purification.

The instruction book of the kit of the invention describes how to use the kit for detection, how to judge the tumor development by using the detection result and how to select the treatment scheme.

With the kit of the present invention, LOC730101 can be detected by various methods selected from the group consisting of (including but not limited to): reverse transcription PCR, real-time quantitative PCR, chip detection, southern blotting, northern blotting, or in situ hybridization. The detection mode can be adjusted and changed by those skilled in the art according to actual conditions and needs.

Further, the primer sequences are shown as SEQ ID NO.1 and SEQ ID NO. 2.

The invention provides an application of LOC730101 in screening a candidate drug for preventing or treating laryngeal squamous cell carcinoma.

Further, the steps of screening candidate drugs are as follows:

treating a system expressing or containing LOC730101 with a candidate substance; and

detecting the expression of LOC730101 in said system;

wherein, if said candidate substance reduces the expression of LOC730101, preferably significantly, it indicates that the candidate substance is a candidate for the prevention or treatment of laryngeal squamous cell carcinoma.

In the present invention, the system includes (but is not limited to): a cell system, a subcellular system, a solution system, a tissue system, an organ system, or an animal system. The candidate substances include (but are not limited to): interfering molecules, nucleic acid inhibitors, small molecule compounds designed against LOC730101 or upstream or downstream thereof.

In the present invention, the steps further include: the obtained candidate drugs are subjected to further cell experiments and/or animal experiments to further select and identify drugs useful for preventing, alleviating or treating laryngeal squamous cell carcinoma from the candidate drugs.

The invention provides an application of LOC730101 in preparation of a medicine for preventing or treating laryngeal squamous cell carcinoma.

The medicament comprises a substance inhibiting the expression of LOC 730101.

The substance for inhibiting the expression of LOC730101 comprises a nucleic acid inhibitor, including an interfering molecule which takes LOC730101 or its transcript as a target sequence and can inhibit the expression of LOC730101, such as: shRNA (small hairpin RNA), small interfering RNA (sirna), dsRNA, microrna, antisense nucleic acid, or a construct capable of expressing or forming said shRNA, small interfering RNA, dsRNA, microrna, antisense nucleic acid.

A "Small hairpin RNA (shRNA)" is a non-coding Small RNA molecule capable of forming a hairpin structure, which is capable of inhibiting the expression of a gene via an RNA interference pathway. As described above, shRNA can be expressed from a double-stranded DNA template. The double-stranded DNA template is inserted into a vector, such as a plasmid or viral vector, and then expressed in vitro or in vivo by ligation to a promoter. The shRNA can be cut into small interfering RNA molecules under the action of DICER enzyme in eukaryotic cells, so that the shRNA enters an RNAi pathway. "shRNA expression vector" refers to some plasmids which are conventionally used for constructing shRNA structure in the field, usually, a "spacer sequence" and multiple cloning sites or alternative sequences which are positioned at two sides of the "spacer sequence" are present on the plasmids, so that people can insert DNA sequences corresponding to shRNA (or analogues) into the multiple cloning sites or replace the alternative sequences on the multiple cloning sites in a forward and reverse mode, and RNA after the transcription of the DNA sequences can form shRNA (short Hairpin) structure. The "shRNA expression vector" is completely available by the commercial purchase of, for example, some viral vectors.

The small interfering RNA refers to a short-fragment double-stranded RNA molecule which can degrade specific mRNA by taking mRNA with homologous complementary sequences as a target, and the process is the RNA interference (RNA interference) process. Small interfering RNA can be prepared as a double-stranded nucleic acid form, which contains a sense and an antisense strand, the two strands only in hybridization conditions to form double-stranded. A double-stranded RNA complex can be prepared from the sense and antisense strands separated from each other. Thus, for example, complementary sense and antisense strands are chemically synthesized, which can then be hybridized by annealing to produce a synthetic double-stranded RNA complex.

Further, the substance inhibiting the expression of LOC730101 is siRNA; in a specific embodiment of the invention, the siRNA sequence is shown in SEQ ID NO. 11-12.

The siRNA of the present invention may be chemically synthesized or may be prepared by transcribing an expression cassette in a recombinant nucleic acid construct into single-stranded RNA. The siRNA may be delivered into the cell by using an appropriate transfection reagent, or may also be delivered into the cell using a variety of techniques known in the art.

The invention provides a pharmaceutical composition for treating laryngeal squamous cell carcinoma, which comprises a substance for inhibiting LOC730101 expression and/or other pharmaceutically acceptable carriers compatible with the substance.

The pharmaceutically acceptable carriers include, but are not limited to, diluents, excipients, binders, wetting agents, absorption enhancers, surfactants, humectants, adsorptive carriers, lubricants, buffers, stabilizers, bacteriostats, isotonizing agents, chelating agents, pH control agents.

The pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. Oral administration or injection administration is preferred. The pharmaceutical composition of the present invention may contain any of the usual non-toxic pharmaceutically acceptable carriers, adjuvants or excipients.

The pharmaceutical composition of the invention can also be used in combination with other drugs for the treatment of squamous cell carcinoma of the larynx, and the other therapeutic compounds can be administered simultaneously with the main active ingredient, even in the same composition. Other therapeutic compounds may also be administered alone in a composition or dosage form different from the main active ingredient.

Preferably, it can be carried out by means of gene therapy. For example, a substance that inhibits the expression of LOC730101 (e.g., siRNA, shRNA) can be directly administered to a subject by a method such as injection; alternatively, the expression unit can be delivered to the target site by a route known to those skilled in the art.

The present invention also provides a method for diagnosing laryngeal squamous cell carcinoma, the method comprising the steps of:

(1) obtaining suspected diseased tissue of the throat of a subject;

(2) detecting the expression level of LOC730101 in the tissue of step 1;

(3) correlating the measured expression level of LOC730101 with the presence or absence of disease in the subject.

(4) If the expression level of LOC730101 in the suspected diseased tissue in the larynx of the subject is significantly increased compared to the normal control, the subject is judged to have laryngeal squamous cell carcinoma, or the subject is judged to have a high risk of laryngeal squamous cell carcinoma, or a patient with laryngeal squamous cell carcinoma is judged to have a relapse, or a patient with laryngeal squamous cell carcinoma is judged to have a poor prognosis.

In the context of the present invention, a "normal control" may refer to a normal human not suffering from laryngeal squamous cell carcinoma, but also to the paracancerous tissues of a human suffering from laryngeal squamous cell carcinoma.

In the context of the present invention, "diagnosing" includes determining whether a subject has suffered a disease, determining whether a subject is at risk of suffering a disease, determining whether a patient has relapsed, determining the responsiveness of a patient to a drug treatment, or determining the prognosis of a patient.

Drawings

FIG. 1 is a graph showing the results of the effect of LncRNA expression on the proliferation of laryngeal squamous cell carcinoma cells;

FIG. 2 is a graph showing the results of the effect of LncRNA expression on the migration of laryngeal squamous cell carcinoma cells.

Detailed Description

The present invention will be described in further detail with reference to the accompanying drawings and examples. The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. Experimental procedures without specific conditions noted in the examples, generally following conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the laboratory Manual (New York: Cold spring harbor laboratory Press, 1989), or according to the manufacturer's recommendations.

Example 1 differential expression molecule validation

First, research object

Cancer tissues and corresponding paracancerous tissues were collected from 45 patients with laryngeal squamous cell carcinoma. Exclusion criteria were included: firstly, the patient has no primary tumor at other parts except the primary tumor, and the primary tumor is not transferred; ② there is no history of cardiovascular and cerebrovascular diseases such as diabetes, hypertension, etc.; thirdly, the history of infectious diseases such as hepatitis, syphilis, tuberculosis, HIV and the like is avoided; fourthly, no history of family hereditary diseases; before operation, radiotherapy, chemotherapy and biological treatment are not performed.

Taking sample precautions: when the tumor specimen is cut, the non-necrotic tumor tissue in the central area of the tumor is cut, the normal tissue beside the cancer is cut away from the tumor as far as possible and is more than 1.5cm away from the edge of the tumor, and the mucosal epithelial tissue is cut as far as possible to avoid the deep connective tissue.

Second, tissue total RNA extraction

Tissue total RNA was extracted using the Norgen RNA extraction kit:

tissue lysis

1) Weighing about 20 mg of the isolated tissue sample in a clean area with less RNase interference by using a mortar containing a proper amount of liquid nitrogen, and grinding the sample into powder by using a pestle;

2) transferring the sample to a 2 mL centrifuge tube without RNase;

3) adding 300uL lysine solution, placing in a homogenizer, and grinding for 1-5 min;

4) 12000 g, centrifuging for 10min at 4 ℃, transferring supernatant into a new centrifuge tube with the volume of 1.5 mL;

5) adding 600ul RNase-Free Water, and mixing with a vortex machine;

6) adding 20ul protease K, bathing at 55 deg.C for 15min, and continuously vortex and mixing;

7) 14000 g, centrifuging for 1min at room temperature to precipitate cell debris at the bottom of the centrifuge tube, taking supernatant and transferring the supernatant into another centrifuge tube without 1.5 mL of RNase;

8) adding 450ul of 95% ethanol, and mixing by vortex;

RNA adsorption:

9) adding 650ul of lysate containing ethanol into a centrifugal column, and centrifuging for 1min at 14000 g;

10) abandoning the lower layer, and resetting the collecting pipe on the column;

11) repeating the steps from 9) to 10) according to the volume of the lysate;

12) adding 400ul Wash solution, 14000 g, and centrifuging for 2 min;

13) abandoning the lower layer, and placing the column on a new collecting pipe;

and (3) DNase treatment:

14) adding 100ul enzyme incorporation Buffer and 15ul DNase I, and centrifuging for 1min at 14000 g;

15) moving the solution in the collecting pipe into the column again;

16) standing at room temperature for 15 min;

RNA washing:

17) adding 400ul Wash solution, centrifuging at 14000 g for 1min, discarding the lower layer, and resetting the collection tube on the column;

18) adding 400ul Wash solution, 14000 g, centrifuging for 2min, and discarding the collecting pipe;

RNA elution:

19) the column was placed in a 1.7mL Elution tube;

20) adding 30ul of Elution Buffer;

21) centrifuge at 200 g for 2min to allow the solution to bind well to the column, and then centrifuge at 14000 g for 1 min.

Third, reverse transcription

The reverse transcription kit (DDR 037A) was purchased from Bao bioengineering (Dalian) Co., Ltd.

Taking the extracted total RNA (1 mu g) as a template, adding a reaction system which comprises 5 × PrimeScript Buffer 4 mu L, PrimeScript RT Enzyme Mix 1 mu L, Oligo dT Primer (50 mu M) 1 mu L, Random 6 mers (100 mu M) 1 mu L and RNase-free ddH₂O make up the reaction volume to 20. mu.L. The mixture was incubated at 37 ℃ for 15min and 85 ℃ for 5s to obtain cDNA. The cDNA can be used for IncRNA Real-time PCR detection.

IV, QPCR

SYBR Premix ExTaq for fluorescent Real-time (Real-time) quantitative PCR (polymerase chain reaction)^TM(Tli RNaseH Plus) kit was manufactured by Takara, Japan. The operation was performed as per the instructions.

By using 2^-△△CtAnd analyzing the expression level of LncRNA by a relative quantification method, wherein Ct is the intensity value of a fluorescence signal detected in a reaction system by a thermal cycler. The calculation method comprises the following steps: delta Ct = (Ct target gene-Ct internal reference gene) cancer tissue experimental group- (Ct target gene-Ct internal reference gene) control tissue group, 2^-△△CtThe expression of the target gene in the experimental group is shown as the fold change relative to the control group, and the analysis of the experimental data is performed by the Bio-RAD analysis software.

Designing a primer: primers were designed by the Primer design tool of NCBI (Primer BLAST) based on LncRNA sequence as follows:

LOC730101

an upstream primer: 5'-TGGATACGGCACAGATTA-3' (SEQ ID NO. 1); a downstream primer: 5'-CAACGATGGATGGATGAC-3' (SEQ ID NO. 2).

LOC442028

An upstream primer: 5'-TCGCATATCATCAACACAAC-3' (SEQ ID NO. 3); a downstream primer: 5'-ACCTGGAAGTTAATGTCTCA-3' (SEQ ID NO. 4).

LOC100507437

An upstream primer: 5'-GTGAACAAGGTGGATTGC-3' (SEQ ID NO. 5); a downstream primer: 5'-GCTGGATTCTTCTTAATTCTTTG-3' (SEQ ID NO. 6).

LOC158435

An upstream primer: 5'-GGTGTGCCTATATGTGAA-3' (SEQ ID NO. 7);

a downstream primer: 5'-CGAGTCAGAATGTTATGC-3' (SEQ ID NO. 8).

Primers were designed based on the GAPDH (internal reference gene) sequence, the upstream primer: 5'-CTCTGGTAAAGTGGATATTGT-3' (SEQ ID NO. 9); 5'-GGTGGAATCATATTGGAACA-3' (SEQ ID NO. 10).

Fifth, statistical analysis

Statistical software SPSS19.0 is adopted for data analysis, and paired T test is used for judging whether the LncRNA expression in cancer tissues and cancer adjacent tissue samples has statistical difference. The statistical tests are all double-sided tests,Pdifferences < 0.05 are statistically significant.

Sixthly, the results

As shown in Table 1, the mean levels of LOC730101, LOC442028, LOC100507437 and LOC158435 expression in the cancer tissues of the laryngeal squamous cell carcinoma patients were significantly increased compared with those in the paracancerous tissues, and the differences among the groups had statistical significance (see (B) (B))P<0.05）。

TABLE 1 LncRNA expression statistics

Example 2 LncRNA silencing

1. Cell culture

Human laryngeal squamous carcinoma cell line Hep2, cultured in RPMI1640 medium containing 10% fetal calf serum and 1% P/S at 37 deg.C and 5% CO₂And culturing in an incubator with relative humidity of 90%. The liquid is changed for 1 time in 2-3 days, the cells grow well and grow in a monolayer adherent manner. Passage was routinely digested with 0.25% EDTA-containing trypsin.

2. Transfection

1) Treatment of cells prior to transfection

One day before transfection, 3-5 × are planted on 6-hole culture plates10⁵And (3) culturing each cell/hole in an antibiotic-free culture medium for one day, wherein the cell density is 30-50% during transfection, and the cell/hole is replaced by a serum-free culture medium before transfection.

2) Design of siRNA

Experiment set-up 2 groups: negative control group (siNC, transfection negative control siRNA), siLncRNA silencing group (transfection siRNA against LncRNA).

Wherein, the siRNA (si LOC 730101) sequence aiming at LOC730101 is as follows:

the sense strand is 5'-UAACAGAACUUAACAUCACCAtt-3' (SEQ ID NO. 11); antisense strand: 5'-GUGAUGUUAAGUUCUGUUAGGtt-3' (SEQ ID NO. 12).

Wherein, the siRNA (si LOC 442028) sequence aiming at LOC442028 is as follows:

the sense strand is 5'-UCAAUGUAAGCAAUGAUUCUGtt-3' (SEQ ID NO. 13),

the antisense strand is 5'-GAAUCAUUGCUUACAUUGACAtt-3' (SEQ ID NO. 14).

Wherein, the siRNA (si LOC 100507437) sequence aiming at LOC100507437 is as follows:

the sense strand is 5'-UUUUGAGAGUUUACUAAACGUtt-3' (SEQ ID NO. 15),

the antisense strand was 5'-GUUUAGUAAACUCUCAAAAGAtt-3' (SEQ ID NO. 16).

Wherein, the siRNA (si LOC 158435) sequence aiming at LOC158435 is as follows:

the sense strand is 5'-UUCUCUAACUCGAUACAGGAUtt-3' (SEQ ID NO. 17),

the antisense strand is 5'-CCUGUAUCGAGUUAGAGAAAUtt-3' (SEQ ID NO. 18).

The universal negative control sirna (sinc) sequence is provided by shanghai gimar pharmaceutical technology ltd.

3) Transfection

a. Taking 3 mu l of siRNA with the concentration of 50pmol, adding 47 mu l of serum-free culture medium, gently mixing uniformly, and incubating for 5min at room temperature;

b. mu.l of Lipofectamine 2000 was added to 49. mu.l of serum-free medium. Mixing, and incubating at room temperature for 5 min;

c. mixing the above two mixtures (total volume 100 μ l), gently mixing, and incubating at room temperature for 25min to allow complex formation;

d. adding 100 mul of compound and a proper amount of culture medium into each hole of a 6-hole plate, and gently mixing uniformly;

e. and observing the silencing effect of the gene after incubation for 48-96 h.

3. Cell transfection efficiency assay

The results of the measurement of the interference of the target gene by the QPCR method described in example 1 show that the sirncrnas of the present invention all have an interference efficiency of 70% or more, and can be used as effective sirnas for the subsequent functional studies.

Example 3 Effect of LncRNA expression on laryngeal squamous carcinoma cell proliferation

The WST-1 method detects the influence of LncRNA expression on the proliferation of laryngeal squamous cell carcinoma cells.

The following day of cell transfection, cell density was adjusted to 1 × 10²Mu.l, seeded in 96-well plates (100. mu.l/well) with 3 duplicate wells per set. 37 ℃ and 5% CO₂After 72 hours of culture, 10. mu.l of WST-1 was added and incubated for 2 hours, and then the optical density (D) of the cells was measured at a wavelength of 450nm in a microplate reader.

The results are shown in FIG. 1, and the differences between groups are statistically significant (.)P<0.05，**P<0.05). Shows that the LOC730101, LOC442028, LOC100507437 and LOC158435 expression can inhibit the proliferation of laryngeal squamous cell carcinoma cells after being inhibited.

Example 4 Effect of LncRNA expression on laryngeal squamous carcinoma cell migration

The following day of cell transfection, the treated cells were collected and counted at 1 × 10⁵The individual cells were resuspended in 100. mu.l serum-free medium and added to the upper chamber of a Transwell cell culture plate, and 600. mu.l complete medium was added to the lower chamber. At 37 ℃ 5% CO₂After 48h incubation, the chamber was removed, the cells in the upper chamber were gently wiped off with a cotton swab, fixed in 4% paraformaldehyde for 20min, washed 1 time with PBS, stained with crystal violet for 10min, washed 1 time with PBS, and the total number of cells in the upper, lower, left, right, and middle 5 different fields was counted under an optical microscope (× 200) and averaged for 3 replicates.

The results are shown in FIG. 2Differences between groups are statistically significant (.)P<0.05，**P<0.01，***P<0.005). The LOC730101, LOC442028 and LOC100507437 expressions are inhibited to inhibit the cell migration of laryngeal squamous carcinoma, while the LOC158435 expression is inhibited to have no influence on the cell migration of laryngeal squamous carcinoma.

The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.

Sequence listing

<110> Beijing, the deep biometric information technology GmbH

<120> application of long-chain non-coding RNA in cancer diagnosis and treatment

<160>18

<170>SIPOSequenceListing 1.0

<210>1

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>1

tggatacggc acagatta 18

<210>2

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>2

caacgatgga tggatgac 18

<210>3

<211>20

<212>DNA

<213> Artificial sequence (artificacial sequence)

<400>3

tcgcatatca tcaacacaac 20

<210>4

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>4

acctggaagt taatgtctca 20

<210>5

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>5

gtgaacaagg tggattgc 18

<210>6

<211>23

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>6

gctggattct tcttaattct ttg 23

<210>7

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>7

ggtgtgccta tatgtgaa 18

<210>8

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>8

cgagtcagaa tgttatgc 18

<210>9

<211>21

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>9

ctctggtaaa gtggatattg t 21

<210>10

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>10

ggtggaatca tattggaaca 20

<210>11

<211>23

<212>DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400>11

uaacagaacu uaacaucacc att 23

<210>12

<211>23

<212>DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400>12

gugauguuaa guucuguuag gtt 23

<210>13

<211>23

<212>DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400>13

ucaauguaag caaugauucu gtt 23

<210>14

<211>23

<212>DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400>14

gaaucauugc uuacauugac att 23

<210>15

<211>23

<212>DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400>15

uuuugagagu uuacuaaacg utt 23

<210>16

<211>23

<212>DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400>16

guuuaguaaa cucucaaaag att 23

<210>17

<211>23

<212>DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400>17

uucucuaacu cgauacagga utt 23

<210>18

<211>23

<212>DNA/RNA

<213> Artificial Sequence (Artificial Sequence)

<400>18

ccuguaucga guuagagaaa utt 23

Claims

1. The application of the reagent for detecting the expression of the long-chain non-coding RNA in the preparation of products for diagnosing laryngeal squamous cell carcinoma; the long non-coding RNA is LOC 730101.

2. The use according to claim 1, wherein the agent comprises: the reagent for detecting the expression level of LOC730101 by reverse transcription PCR, real-time quantitative PCR, immunodetection, in-situ hybridization or chip technology.

3. Use according to claim 2, wherein said agent comprises a nucleic acid binding to LOC730101 or a DNA sequence thereof.

4. The use according to claim 3, wherein said nucleic acid comprises a primer directed to LOC 730101.

5. The use according to claim 4, wherein the primer has the sequence shown in SEQ ID No. 1-2.

6. A product for diagnosing laryngeal squamous carcinoma, wherein the product comprises the agent of any one of claims 1 to 5.

7. The product of claim 6, wherein the product is a chip, a kit, a strip, or a high throughput sequencing platform.

Use of LOC730101 in the screening of a candidate drug for the prevention or treatment of laryngeal squamous cell carcinoma.

Application of LOC730101 in preparation of medicine for preventing or treating laryngeal squamous cell carcinoma is provided.

10. The use according to claim 9, wherein the medicament comprises a substance that inhibits the expression of LOC 730101.

11. The use according to claim 10, wherein the substance that inhibits the expression of LOC730101 comprises a nucleic acid inhibitor comprising shRNA, small interfering RNA, dsRNA, microrna, antisense nucleic acid, or a construct capable of expressing or forming said shRNA, small interfering RNA, dsRNA, microrna, antisense nucleic acid.

12. The use of claim 11, wherein the nucleic acid inhibitor is an siRNA.

13. The use according to claim 12, wherein the siRNA sequence is as set forth in SEQ ID No. 11-12.